Lemtrada (alemtuzumab) / Sanofi 
Welcome,         Profile    Billing    Logout  
 8 Diseases   17 Trials   17 Trials   2602 News 


«12...13141516171819202122232425»
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Trial completion date, Trial primary completion date:  LEMTRADA Pregnancy Registry in Multiple Sclerosis (clinicaltrials.gov) -  Aug 6, 2019   
    P=N/A,  N=204, Recruiting, 
    Trial completion date: May 2020 --> Nov 2022 | Trial primary completion date: May 2020 --> Nov 2022
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Clinical, Journal:  Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis. (Pubmed Central) -  Aug 1, 2019   
    Whether this is due to different rates of B- and T cell repopulation has to be the subject of further research. Moreover, further effects on the interactions between the adaptive and innate immunity as well as between B and T cell lineages might explain the observed disease activation.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Journal:  Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis. (Pubmed Central) -  Aug 1, 2019   
    The aim is to illustrate the clinical presentation, evaluation over time, and the possibility to consider a conservative management up to the spontaneous resolution of the thyrotoxicosis. All these are intended to emphasize the importance of pretreatment screening and follow-up in the management of treatment with alemtuzumab.
  • ||||||||||  Zinbryta (daclizumab) / Biogen, AbbVie, Lemtrada (alemtuzumab) / Sanofi
    Review, Journal:  Monoclonal Antibodies for Multiple Sclerosis: An Update. (Pubmed Central) -  Jul 19, 2019   
    While it is very unlikely that monoclonal antibodies will ever cure MS, they have become very valuable therapeutic tools to better patient outcomes. This review focuses on developments of monoclonal antibodies used in the past, present, and near future in MS patients.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Clinical, Journal:  Therapeutic Outcome of Alemtuzumab in Korean Patients with Multiple Sclerosis: 2-Year Follow-Up. (Pubmed Central) -  Jul 10, 2019   
    Although most alemtuzumab-treated patients experienced IARs as in previous controlled clinical studies, there was an improvement in the frequency and distribution of alemtuzumab-associated rash, which may have been associated with this study's prophylaxis regimen. Consistent with observations in Western populations, alemtuzumab therapy in Korean MS patients led to marked reductions of disease activity without unexpected safety issues.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Journal:  Autoimmune encephalitis following alemtuzumab treatment of multiple sclerosis. (Pubmed Central) -  Jun 15, 2019   
    Although testing for anti-neuronal antibodies was negative, the patient responded well to immunotherapy including plasma exchange. This is the first reported presentation of an autoimmune encephalopathy secondary to alemtuzumab therapy.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Clinical, Journal:  Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis. (Pubmed Central) -  Jun 15, 2019   
    In addition to cellular depletion, bystander effects including transient cell activation and triggered cytokine release are thought to cause alemtuzumab-specific IARs. We describe acute laboratory changes during first alemtuzumab infusion week in a RRMS patient, underling acute changes in immunological and routine laboratory parameters.
  • ||||||||||  Gilenya (fingolimod) / Novartis, Mitsubishi Tanabe, Rituxan (rituximab) / Roche, Biogen, Lemtrada (alemtuzumab) / Sanofi
    Journal:  Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. (Pubmed Central) -  Jun 7, 2019   
    This case report adds to the growing body of literature of B-cell-associated disease activation after alemtuzumab infusion and provides a therapeutic strategy to stabilize patients when rituximab is not readily available or if contraindications to its use exist. Treating RRMS patients with alemtuzumab or rituximab after fingolimod withdrawal is effective and safe, without significant differences between both groups in our series.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    Clinical, Journal, Adverse events:  Provision of alemtuzumab safety is one of the main components of pharmacovigilance (Pubmed Central) -  Jun 4, 2019   
    This article presents a clinical case of lethal listeriosis meningoencephalitis, which developed within 7 days after the completion of the first cycle of alemtuzumab therapy. In January 2018, a meeting of the expert Council was held, at which the clinical recommendations published in 2017 were revised and updated.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Journal:  Alemtuzumab depletion failure can occur in multiple sclerosis. (Pubmed Central) -  May 30, 2019   
    Thus, although alemtuzumab depletes lymphocytes in most individuals, some people fail to deplete/deplete-poorly, probably due to biological-response variation and NAbs and this may lead to treatment failure. Monitoring depletion following infusion and assessment of neutralizing response prior to re-infusion may help inform the decision to retreat or switch therapy to limit treatment failure.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Clinical, Journal:  Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS. (Pubmed Central) -  May 25, 2019   
    ...We investigated 15 patients with MS after immune reconstitution treatment with alemtuzumab (ATZ)...During 2 documented pregnancies, sNfL was at a low level, whereas a postpartum transient sNfL increase was seen without any signs of activity. This study applied a long-term high-frequency sNfL assessment in an ATZ-treated cohort, allowing a holistic profiling on the individual level and highlighted that sNfL can eminently complement the individual clinical and MRI monitoring in clinical practice.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    Clinical, PK/PD data, Review, Journal:  Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation. (Pubmed Central) -  May 17, 2019   
    There is a need for pharmacokinetic and dose-finding studies of alemtuzumab in kidney transplant recipients to establish the optimal balance between efficacy and toxicity. Furthermore, randomized controlled trials with sufficient follow-up are necessary to provide further evidence for the treatment of severe kidney transplant rejection.
  • ||||||||||  Tysabri (natalizumab) / Biogen, Gilenya (fingolimod) / Novartis, Mitsubishi Tanabe, Lemtrada (alemtuzumab) / Sanofi
    Clinical, Journal:  Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation. (Pubmed Central) -  May 8, 2019   
    Furthermore, randomized controlled trials with sufficient follow-up are necessary to provide further evidence for the treatment of severe kidney transplant rejection. Our findings indicated particular advantages of ALEM compared to FTY in patients stopping NTZ.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Enrollment change, Trial termination:  CAM-THY: Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis (clinicaltrials.gov) -  Apr 30, 2019   
    P1/2,  N=40, Terminated, 
    Our findings indicated particular advantages of ALEM compared to FTY in patients stopping NTZ. N=86 --> 40 | Recruiting --> Terminated; interim anlaysis failed: palifermin does not promote thymopoeisis after alemtuzumab
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Trial completion date, Trial primary completion date:  TOPAZ: Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 (clinicaltrials.gov) -  Apr 19, 2019   
    P4,  N=812, Active, not recruiting, 
    N=86 --> 40 | Recruiting --> Terminated; interim anlaysis failed: palifermin does not promote thymopoeisis after alemtuzumab Trial completion date: Mar 2020 --> Jun 2020 | Trial primary completion date: Mar 2020 --> Jun 2020
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    Journal:  Lambert-Eaton myasthenic syndrome associated with alemtuzumab administration. (Pubmed Central) -  Apr 18, 2019   
    Physicians dealing with this drug should be aware of this serious but treatable complication. Alemtuzumab treatment can result in the development of neurologic autoimmune conditions that could mimic MS progression.